EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudie

Safety profile of enfortumab vedotin plus pembrolizumab in locally advanced or metastatic urothelial carcinoma: a multicenter Japanese cohort study

Kosuke Iwatani iD, Fumihiko Urabe iD, Keiichiro Mori, Juria Nakano, Kensuke Fujiwara, Shun Saito, Shuhei Hara, Shota Kawano, Mimu Ishikawa, Wataru Fukuokaya, Yu Imai, Sotaro Kayano und 8 weitere

Japanese Journal of Clinical Oncology · 2026

DOI: 10.1093/jjco/hyaf182 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Japanese Journal of Clinical Oncology, 2026. Verfasst von Kosuke Iwatani und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The Jikei University School of Medicine, 3-25-8 Nishi-shinbashi, Minato-ku, Tokyo 105-8461, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Urologic Neoplasms, Antibodies, Monoclonal. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Enfortumab vedotin plus pembrolizumab (EVP) has shown promising efficacy in locally advanced or metastatic urothelial carcinoma (la/mUC), but real-world data in Japanese patients are limited. We assessed the safety and early efficacy of EVP, with a focus on cutaneous adverse events (AEs).

Methods

We retrospectively analyzed 48 Japanese patients with la/mUC treated with first-line EVP at 12 centers between November 2024 and March 2025. Clinical data, AEs, and tumor responses were collected. Cutaneous AEs were evaluated for onset, severity, and management. Tumor response was assessed using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

Results

The patients’ median age was 76 years, and 89.6% were cisplatin-ineligible. All patients experienced treatment-related AEs, with 39.6% having grade ≥3 events. Cutaneous AEs occurred in 60.4%, including 18.8% with grade ≥3 rash and two cases of Stevens–Johnson syndrome. The median time to discontinuation due to AEs was 14 days. The overall response rate was 39.6%, and the disease control rate was 69%, rising to 87% among 38 evaluable patients.

Conclusion

EVP demonstrated favorable early efficacy in Japanese patients but was associated with frequent early discontinuation due to AEs, particularly cutaneous toxicity. Early skin care and interdisciplinary management are essential. These findings support EVP use while emphasizing AE management and patient-centered care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsUrologic NeoplasmsAntibodies, MonoclonalCarcinoma, Transitional CellUrinary Bladder NeoplasmsHumansAgedMaleFemaleRetrospective StudiesAged, 80 and overMiddle AgedJapanNeoplasm MetastasisCohort StudiesEast Asian People

Stichwörter der Autor:innen

Japanese cohortenfortumab vedotin plus pembrolizumaburothelial carcinoma

Substanzen

Antibodies, Monoclonal, Humanizedpembrolizumabenfortumab vedotinAntibodies, Monoclonal

Autor:innen und Institutionen

  • Department of Urology, The Jikei University School of Medicine, 3-25-8 Nishi-shinbashi, Minato-ku, Tokyo 105-8461, Japan.
  • Department of Urology, Jikei University Kashiwa Hospital, 163-1 Kashiwashita, Kashiwa-shi, Chiba, Tokyo 277-0004, Japan.
  • Department of Urology, Jikei University the 3rd Hospital, 4-11-1 Izumi-honcho, Komae-shi, Tokyo 201-8601, Japan.
  • Department of Urology, JR Tokyo General Hospital, 2-1-3 Yoyogi, Shibuya-ku, Tokyo 151-8528, Japan.
  • Department of Urology, Machida Municipal Hospital, 2-15-41 Asahimachi, Machida-shi, Kanagawa 194-0023, Japan.
  • Department of Urology, Jikei University Katsushika Medical Cener, 6-41-2 Aoto, Katsushika-ku, Tokyo 125-8506, Japan.

ORCID-Profile: Kosuke Iwatani, Fumihiko Urabe, Shunsuke Tsuzuki, Jun Miki, Takahiro Kimura

Zitieren

APA

Iwatani, K., Urabe, F., Mori, K., Nakano, J., Fujiwara, K., Saito, S., Hara, S., Kawano, S., Ishikawa, M., Fukuokaya, W., Imai, Y., Kayano, S., Kasai, K., Yanagisawa, T., Tashiro, K., Murakami, M., Tsuzuki, S., Waki, Y., Miki, J., & Kimura, T. (2026). Safety profile of enfortumab vedotin plus pembrolizumab in locally advanced or metastatic urothelial carcinoma: a multicenter Japanese cohort study. Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyaf182

Vancouver

Iwatani K, Urabe F, Mori K, Nakano J, Fujiwara K, Saito S, et al. Safety profile of enfortumab vedotin plus pembrolizumab in locally advanced or metastatic urothelial carcinoma: a multicenter Japanese cohort study. Japanese Journal of Clinical Oncology. 2026. doi:10.1093/jjco/hyaf182

BibTeX
@article{Iwatani2026,
  author = {Iwatani, Kosuke and Urabe, Fumihiko and Mori, Keiichiro and Nakano, Juria and Fujiwara, Kensuke and Saito, Shun and Hara, Shuhei and Kawano, Shota and Ishikawa, Mimu and Fukuokaya, Wataru and Imai, Yu and Kayano, Sotaro and Kasai, Kanako and Yanagisawa, Takafumi and Tashiro, Kojiro and Murakami, Masaya and Tsuzuki, Shunsuke and Waki, Yuma and Miki, Jun and Kimura, Takahiro},
  title = {Safety profile of enfortumab vedotin plus pembrolizumab in locally advanced or metastatic urothelial carcinoma: a multicenter Japanese cohort study},
  journal = {Japanese Journal of Clinical Oncology},
  year = {2026},
  doi = {10.1093/jjco/hyaf182}
}
Kostenlos starten →